表紙
市場調查報告書
商品編碼
1068003

勃起功能障礙治療藥的全球市場(2021年∼2028年):產業分析,規模,佔有率,成長,趨勢,預測

Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

出版日期: | 出版商: Transparency Market Research | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球勃起功能障礙(ED)治療藥市場調查,市場概要,市場的推動因素與阻礙因素的分析,市場機會,COVID-19影響,市場區隔及各地區的市場分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 序文

第2章 假設調查手法

第3章 摘要整理:全球勃起功能障礙(ED)治療藥市場

第4章 市場概要

  • 簡介
    • 治療藥定義
    • 產業的演進/發展
  • 概要

第5章 市場預測

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 市場機會分析
    • 趨勢
  • 全球勃起功能障礙市場分析與預測(2018年∼2028年)
  • 波特的五力分析
  • 勃起功能障礙治療藥市場價值鏈分析
  • 開發平台分析
    • 發現
    • 臨床前
    • IND(臨床實驗藥)
    • I期
    • I/II期
    • II期
    • III期
    • 預登記
  • 全球勃起功能障礙(ED)治療藥市場預測

第6章 全球勃起功能障礙(ED)治療藥市場分析與預測:各治療藥物

  • 簡介和定義
  • 主要調查結果/開發
  • 市場價值預測(2018年∼2028年)
    • Viagra
    • Cialis
    • Staxyn/Levitra
    • Stendra/Spedra
    • 其他
  • 市場魅力分析

第7章 全球勃起功能障礙(ED)治療藥市場分析與預測:各流通管道

  • 簡介和定義
  • 主要調查結果/開發
  • 市場價值預測(2018年∼2028年)
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場魅力分析

第8章 全球勃起功能障礙(ED)治療藥市場分析與預測:各地區

  • 主要調查結果
  • 市場價值預測
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲
  • 各地區的市場魅力分析

第9章 勃起功能障礙(ED)治療藥市場分析與預測:北美

  • 簡介
    • 主要調查結果
  • 市場價值預測,各治療藥物(2018年∼2028年)
    • Viagra
    • Cialis
    • Staxyn/Levitra
    • Stendra/Spedra shiarisu
    • 其他
  • 市場價值預測,各流通管道(2018年∼2028年)
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場價值預測,各國(2018年∼2028年)
    • 美國
    • 加拿大

第10章 勃起功能障礙(ED)治療藥市場分析與預測:歐洲

第11章 勃起功能障礙(ED)治療藥市場分析與預測:亞太地區

第12章 勃起功能障礙(ED)治療藥市場分析與預測:南美

第13章 勃起功能障礙(ED)治療藥市場分析與預測:中東、非洲

第14章 競爭情形

  • 市場企業:競爭矩陣(企業的層和各規模)
  • 市場收益佔有率分析(2020年):各企業
  • 有競爭力的商務策略
  • 企業簡介
    • Pfizer, Inc.
    • Dong-A ST Co., Ltd.
    • Eli Lilly and Company
    • Bayer AG
    • VIVUS, INC.
    • SK chemicals
    • Meda Pharmaceuticals, Inc.
    • Cristalia Produtos Quimicos Farmaceuticos Ltda.
    • Apricus Biosciences, Inc.
    • Teva Pharmaceutical Industries Ltd.
目錄
Product Code: TMRGL1550

Scope of the Report

TMR's report on the global erectile dysfunction (ED) drugs market studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides revenue of the global erectile dysfunction (ED) drugs market for the period 2020-2028, considering 2020 as the base year and 2021 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global erectile dysfunction (ED) drugs market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global erectile dysfunction (ED) drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global erectile dysfunction (ED) drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global erectile dysfunction (ED) drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global erectile dysfunction (ED) drugs market.

The report delves into the competition landscape of the global erectile dysfunction (ED) drugs market. Key players operating in the global erectile dysfunction (ED) drugs market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global erectile dysfunction (ED) drugs market that have been profiled in this report.

Key Questions Answered:

  • What is the scope of growth of product companies in the global erectile dysfunction (ED) drugs market?
  • What will be the Y-o-Y growth of the global erectile dysfunction (ED) drugs market between 2020 and 2028?
  • What is the influence of changing trends in technologies on the global erectile dysfunction (ED) drugs market?
  • Will North America be the most profitable market for medical device technology providers?
  • Which factors are anticipated to hamper the growth of the global erectile dysfunction (ED) drugs market during the forecast period?
  • Which are the leading companies in the global erectile dysfunction (ED) drugs market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global erectile dysfunction (ED) drugs market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global erectile dysfunction (ED) drugs market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR's study on the erectile dysfunction (ED) drugs market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the erectile dysfunction (ED) drugs market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global erectile dysfunction (ED) drugs market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR's estimates on future prospects of the global erectile dysfunction (ED) drugs market more reliably and accurately.

Table of Contents

1. Preface

  • 1.1. Market Segmentation
  • 1.2. Key Research Objectives
  • 1.3. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Secondary Research Methodology
  • 2.2. Primary Research Methodology
  • 2.3. Analysis Research Methodology

3. Executive Summary: Global Erectile Dysfunction (ED) Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview

5. Market Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Opportunity Analysis
    • 5.1.5. Trends
  • 5.2. Global Erectile Dysfunction Market Analysis and Forecast, 2018-2028
  • 5.3. Porter's Five Forces Analysis
  • 5.4. Erectile Dysfunction Drugs Market Value Chain Analysis
  • 5.5. Pipeline Analysis
    • 5.5.1. Discovery
    • 5.5.2. Preclinical
    • 5.5.3. IND (Investigational New Drug)
    • 5.5.4. Phase I
    • 5.5.5. Phase I/II
    • 5.5.6. Phase II
    • 5.5.7. Phase III
    • 5.5.8. Pre-registration
  • 5.6. Global Erectile Dysfunction (ED) Drug Market Outlook

6. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Drug

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug, 2018-2028
    • 6.3.1. Viagra
    • 6.3.2. Cialis
    • 6.3.3. Staxyn/Levitra
    • 6.3.4. Stendra/Spedra
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Drug

7. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2018-2028
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Drug, 2018-2028
    • 9.2.1. Viagra
    • 9.2.2. Cialis
    • 9.2.3. Staxyn/Levitra
    • 9.2.4. Stendra/Spedra
    • 9.2.5. Others
  • 9.3. Market Value Forecast, by Distribution Channel, 2018-2028
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Value Forecast, by Country, 2018-2028
    • 9.4.1. U.S.
    • 9.4.2. Canada

10. Europe Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug, 2018-2028
    • 10.2.1. Viagra
    • 10.2.2. Cialis
    • 10.2.3. Staxyn/Levitra
    • 10.2.4. Stendra/Spedra
    • 10.2.5. Others
  • 10.3. Market Value Forecast, by Distribution Channel, 2018-2028
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Value Forecast, by Country/Sub-region, 2018-2028
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Rest of Europe

11. Asia Pacific Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug, 2018-2028
    • 11.2.1. Viagra
    • 11.2.2. Cialis
    • 11.2.3. Staxyn/Levitra
    • 11.2.4. Stendra/Spedra
    • 11.2.5. Others
  • 11.3. Market Value Forecast, by Distribution Channel, 2018-2028
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
  • 11.4. Market Value Forecast, by Country/Sub-region, 2018-2028
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific

12. Latin America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug, 2018-2028
    • 12.2.1. Viagra
    • 12.2.2. Cialis
    • 12.2.3. Staxyn/Levitra
    • 12.2.4. Stendra/Spedra
    • 12.2.5. Others
  • 12.3. Market Value Forecast, by Distribution Channel, 2018-2028
    • 12.3.1. Hospital Pharmacies
    • 12.3.2. Retail Pharmacies
    • 12.3.3. Online Pharmacies
  • 12.4. Market Value Forecast, by Country/Sub-region, 2018-2028
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America

13. Middle East & Africa Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug, 2018-2028
    • 13.2.1. Viagra
    • 13.2.2. Cialis
    • 13.2.3. Staxyn/Levitra
    • 13.2.4. Stendra/Spedra
    • 13.2.5. Others
  • 13.3. Market Value Forecast, by Distribution Channel, 2018-2028
    • 13.3.1. Hospital Pharmacies
    • 13.3.2. Retail Pharmacies
    • 13.3.3. Online Pharmacies
  • 13.4. Market Value Forecast, by Country/Sub-region, 2018-2028
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (by tier and size of companies)
  • 14.2. Market Share Analysis, by Company, 2020
  • 14.3. Competitive Business Strategies
  • 14.4. Company Profiles
    • 14.4.1. Pfizer, Inc.
      • 14.4.1.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.1.2. Product Portfolio
      • 14.4.1.3. SWOT Analysis
      • 14.4.1.4. Strategic Overview
    • 14.4.2. Dong-A ST Co., Ltd.
      • 14.4.2.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.2.2. Product Portfolio
      • 14.4.2.3. SWOT Analysis
      • 14.4.2.4. Strategic Overview
    • 14.4.3. Eli Lilly and Company
      • 14.4.3.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.3.2. Product Portfolio
      • 14.4.3.3. SWOT Analysis
      • 14.4.3.4. Strategic Overview
    • 14.4.4. Bayer AG
      • 14.4.4.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.4.2. Product Portfolio
      • 14.4.4.3. SWOT Analysis
      • 14.4.4.4. Strategic Overview
    • 14.4.5. VIVUS, INC.
      • 14.4.5.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.5.2. Product Portfolio
      • 14.4.5.3. SWOT Analysis
      • 14.4.5.4. Strategic Overview
    • 14.4.6. SK chemicals
      • 14.4.6.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.6.2. Product Portfolio
      • 14.4.6.3. SWOT Analysis
      • 14.4.6.4. Strategic Overview
    • 14.4.7. Meda Pharmaceuticals, Inc.
      • 14.4.7.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.7.2. Product Portfolio
      • 14.4.7.3. SWOT Analysis
      • 14.4.7.4. Strategic Overview
    • 14.4.8. Cristalia Produtos Quimicos Farmaceuticos Ltda.
      • 14.4.8.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.8.2. Product Portfolio
      • 14.4.8.3. SWOT Analysis
      • 14.4.8.4. Strategic Overview
    • 14.4.9. Apricus Biosciences, Inc.
      • 14.4.9.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.9.2. Product Portfolio
      • 14.4.9.3. SWOT Analysis
      • 14.4.9.4. Strategic Overview
    • 14.4.10. Teva Pharmaceutical Industries Ltd.
      • 14.4.10.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.10.2. Product Portfolio
      • 14.4.10.3. SWOT Analysis
      • 14.4.10.4. Strategic Overview

List of Tables

  • Table 01: Global Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028
  • Table 02: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028
  • Table 03: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Region, 2018-2028
  • Table 04: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country, 2018-2028
  • Table 05: North America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028
  • Table 06: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028
  • Table 07: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2028
  • Table 08: Europe Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028
  • Table 09: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028
  • Table 10: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2028
  • Table 11: Asia Pacific Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028
  • Table 12: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028
  • Table 13: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2028
  • Table 14: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028
  • Table 15: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028
  • Table 16: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2028
  • Table 17: Latin America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028
  • Table 18: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028
  • Table 19: Pfizer, Inc. Products Offered
  • Table 20: Pfizer, Inc. Recent Developments
  • Table 21: Dong-A ST Co., Ltd. Products Offered
  • Table 22: Dong-A ST Co., Ltd. Recent Developments
  • Table 23: Eli Lilly and Company Products Offered
  • Table 24: Eli Lilly and Company Recent Developments
  • Table 25: Bayer AG Products Offered
  • Table 26: Bayer AG Recent Developments
  • Table 27: VIVUS, INC. Ltd. Products Offered
  • Table 28: VIVUS, INC. Recent Developments
  • Table 29: SK chemicals Products Offered
  • Table 30: SK chemicals Recent Developments
  • Table 31: Meda Pharmaceuticals Inc. Products Offered
  • Table 32: Meda Pharmaceuticals Inc. Recent Developments
  • Table 33: Cristalia Produtos Quimicos Farmaceuticos Ltda. Products Offered
  • Table 34: Cristalia Produtos Quimicos Farmaceuticos Ltda. Recent Developments
  • Table 35: Apricus Biosciences, Inc. Products Offered
  • Table 36: Apricus Biosciences, Inc. Recent Developments
  • Table 37: Teva Pharmaceutical Industries Ltd. Products Offered

List of Figures

  • Figure 01: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, 2020-2028
  • Figure 02: Market Value Share, by Drug Class (2020)
  • Figure 03: Market Value Share, by Distribution Channel (2020)
  • Figure 04: Market Value Share, by Region (2020)
  • Figure 05: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028
  • Figure 06: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Viagra, 2020-2028
  • Figure 07: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Cialis, 2020-2028
  • Figure 08: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Staxyn/Levitra, 2020-2028
  • Figure 09: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Stendra/Spedra, 2020-2028
  • Figure 10: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by others, 2020-2028
  • Figure 11: Global Erectile Dysfunction (ED) Drug Market Value Share Analysis, by Distribution channel, 2020 and 2028
  • Figure 12: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2020-2028
  • Figure 13: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2020-2028
  • Figure 14: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacies, 2020-2028
  • Figure 15: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Region, 2020 and 2028
  • Figure 16: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020-2028
  • Figure 17: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country, 2020 and 2028
  • Figure 18: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028
  • Figure 19: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028
  • Figure 20: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2028
  • Figure 21: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028
  • Figure 22: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028
  • Figure 23: Europe Erectile Dysfunction (ED) Drugs Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2028
  • Figure 24: Asia Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2028
  • Figure 25: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028
  • Figure 26: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2020 and 2028
  • Figure 27: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028
  • Figure 28: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2028
  • Figure 29: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028
  • Figure 30: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2020 and 2028
  • Figure 31: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028
  • Figure 32: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2028
  • Figure 33: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028
  • Figure 34: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028
  • Figure 35: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028
  • Figure 36: Global Erectile Dysfunction (ED) Drugs Market Share Analysis, by Company (2020)
  • Figure 37: Pfizer, Inc. Breakdown of Net Sales, by Region, 2020
  • Figure 38: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2018-2020
  • Figure 39: Pfizer, Inc. R&D Intensity and Sales & Marketing Intensity - Company Level, 2018-2028
  • Figure 40: Dong-A ST Co., Ltd. Breakdown of Net Sales, by Businesses Segment
  • Figure 41: Dong-A ST Co., Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2018-2020
  • Figure 42: Dong-A ST Co., Ltd. R&D Intensity and Sales & Marketing Intensity - Company Level, 2018-2028
  • Figure 43: Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2018-2020
  • Figure 44: Eli Lilly and Company R&D Intensity and Sales & Marketing Intensity - Company Level, 2018-2028
  • Figure 45: Eli Lilly and Company Breakdown of Net Sales, by Region (Company Level), 2020
  • Figure 46: Eli Lilly and Company Breakdown of Net Sales, (by Endocrinology Level), 2020
  • Figure 47: Bayer AG Breakdown of Net Sales, by Region, 2020
  • Figure 48: Bayer AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2020
  • Figure 49: Bayer AG R&D Intensity and Net Income (US$ Mn) - Company Level, 2020
  • Figure 50: VIVUS, INC. R&D Intensity and Sales & Marketing Intensity - Company Level, 2018-2028
  • Figure 51: VIVUS, INC. Breakdown of Revenue, by Operation (Company Level), 2020
  • Figure 52: VIVUS, INC. Breakdown of Research and Development Expenses, 2020
  • Figure 53: SK chemicals Consolidated Balance Sheet (US$ Bn), 2020
  • Figure 54: SK chemicals Revenue (US$ Bn) and Y-o-Y Growth (%), 2018-2020
  • Figure 55: SK chemicals R&D Intensity and Net Income (US$ Mn) - Company Level, 2018-2020
  • Figure 56: Meda Pharmaceuticals Inc. Breakdown of Net Sales, by Region, 2020
  • Figure 57: Meda Pharmaceuticals Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2020
  • Figure 58: Meda Pharmaceuticals Inc. Selling, Medicine &business development and administrative expenses (US$ Mn) - Company Level, 2018-2020
  • Figure 59: Apricus Biosciences, Inc. Breakdown of Net Sales, by Region, 2020
  • Figure 60: Apricus Biosciences, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2020
  • Figure 61: Apricus Biosciences, Inc. R&D and General & administrative (US$ Mn) - Company Level, 2018-2028
  • Figure 62: Teva Pharmaceutical Industries Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2018-2020
  • Figure 63: Teva Pharmaceutical Industries Ltd. R&D Intensity and Sales & Marketing Intensity (%) - Company Level, 2018-2028
  • Figure 64: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region 2020
  • Figure 65: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, (Overall Company Level), 2020